Vol. 18/No. 01 | OncologyLive

Thinking Big

January 05, 2017

Although it’s easy to become jaded about the prospects for positive change in any bureaucracy, we are feeling decidedly upbeat about the developments underway on the federal level concerning the cancer research behemoth.

Immunotherapies Form New Frontier in Treating Head and Neck Cancers

January 02, 2017

In August 2016, the FDA approved pembrolizumab for patients with platinum-refractory squamous cell carcinoma of the head and neck. Not only was it the first immunotherapy approved for head and neck cancer (HNC), but it marked the first new drug approval for HNC in the United States in 20 years.

The Big Picture for 2017: 6 Experts Weigh In

January 01, 2017

Two of the most noteworthy developments in the oncology field during 2016 were the continued expansion of checkpoint blockade immunotherapy agents into more cancer types and the federal government’s plans for funding and remaking the research paradigm.

Targeting KIR Opens Door to Promising Immunotherapy Combos

December 30, 2016

Although T cells have commanded most of the attention in the burgeoning immuno-oncology field, there is a growing appreciation that other immune cells have important roles in tumor surveillance and would represent attractive therapeutic targets.

Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer

December 29, 2016

An immunotherapy combination that adds the interleukin-10 agonist AM0010 to FOLFOX chemotherapy will be evaluated in a phase III trial for patients with metastatic pancreatic cancer that could introduce a new modality to the treatment paradigm for the malignancy.